Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 10.99M P/E - EPS this Y 93.20% Ern Qtrly Grth -
Income -14.46M Forward P/E -0.35 EPS next Y - 50D Avg Chg -32.00%
Sales 129.18k PEG - EPS past 5Y - 200D Avg Chg -58.00%
Dividend N/A Price/Book 1.26 EPS next 5Y - 52W High Chg -92.00%
Recommedations 1.50 Quick Ratio 1.21 Shares Outstanding 3.07M 52W Low Chg 57.00%
Insider Own 11.74% ROA -175.81% Shares Float 2.71M Beta 1.11
Inst Own 3.53% ROE - Shares Shorted/Prior 557.46K/232.05K Price 0.33
Gross Margin - Profit Margin - Avg. Volume 3,966,956 Target Price 23.00
Oper. Margin -6,866.05% Earnings Date May 8 Volume 322,774 Change 1.26%
About Sonnet BioTherapeutics Holdings

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6. The company is headquartered in Princeton, New Jersey.

Sonnet BioTherapeutics Holdings News
03/19/24 Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting
03/11/24 Sonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified Objective
04:05 PM Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers
02/17/24 Sonnet BioTherapeutics Holdings First Quarter 2024 Earnings: Beats Expectations
02/14/24 Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update
12/21/23 Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy
12/14/23 Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update
10/31/23 Sonnet BioTherapeutics Provides Fiscal Year 2023 Business Overview
10/25/23 Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering
10/17/23 Sonnet BioTherapeutics Announces Abstract Accepted for Presentation by a Key Opinion Leader at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
09/20/23 Sonnet BioTherapeutics Announces Results of Biodistribution Studies Demonstrating Solid Tumor Targeting Using the FHAB Technology
09/19/23 Sonnet BioTherapeutics Regains Nasdaq Minimum Bid Price Compliance
08/31/23 Sonnet BioTherapeutics Announces 1-for-22 Reverse Stock Split
08/16/23 Sonnet BioTherapeutics Announces FDA Acceptance of the Company's IND for the SB221 Clinical Trial of SON-1010 Combined with Atezolizumab in the US
08/14/23 Sonnet BioTherapeutics Provides Fiscal Year 2023 Third Quarter Business and Earnings Update
07/31/23 Sonnet BioTherapeutics to Present at the 2023 BTIG Virtual Biotechnology Conference
06/28/23 Sonnet BioTherapeutics Announces $2.25 Million Registered Direct Offering and Concurrent Private Placement
06/23/23 Sonnet BioTherapeutics Announces Presentations at the 2023 Cytokine-Based Drug Development Summit and Provides Preliminary Update on the SON-080 Study in Chemotherapy-Induced Peripheral Neuropathy
06/20/23 Sonnet BioTherapeutics Announces Regulatory Approval for Initiation of a Clinical Trial of SON-1010 Combined with Atezolizumab
05/10/23 Sonnet BioTherapeutics Provides Fiscal Year 2023 Second Quarter and Year-to-Date Business and Earnings Update
SONN Chatroom

User Image TheDude79 Posted - 15 hours ago

$SONN I’m so confused . I was certain Pgoddess was markey. Markey get control of your bitch, she’s burning the house down lol

User Image 100Mshelf Posted - 16 hours ago

$SONN Mohan - this is a great resource on succession planning below. Maybe by the time your grandkids are old enough to take over the business the Janssen data will be ready to disclose. https://www2.deloitte.com/content/dam/Deloitte/us/Documents/deloitte-private/us-dges-business-succession-planning-collection.pdf

User Image Tyjelly Posted - 1 day ago

$SONN what a big stinky turd

User Image PennyGoddess Posted - 1 day ago

$SONN I meant 1.60 🤣🤣

User Image PennyGoddess Posted - 1 day ago

$SONN Shake them trees. Let's get this to $1.80

User Image Gratz34 Posted - 1 day ago

$SONN nothing if not predictable.

User Image Jackie_Treehorn Posted - 1 day ago

$SONN when the MMs you partner with are known for naked shorting and shady tactics for funding this is the result! Pure criminals. It’s funny how Sabby cut ties shortly after I reported them to SEC for partnering with them 😂

User Image PennyGoddess Posted - 2 days ago

$SONN Done with this stock.

User Image PennyGoddess Posted - 3 days ago

$SONN Calm before the storm. We will have good news very soon imo.

User Image brotherearl Posted - 3 days ago

$SONN lucky to be loading cheapies! 2.55 soon

User Image Jackie_Treehorn Posted - 3 days ago

$SONN

User Image 100Mshelf Posted - 4 days ago

$SONN How much data did these guys get that they are still reviewing it over a month and half later? Frank Abagnale studied for two weeks and passed the Louisiana bar exam and we are to believe these guys can’t input data into a model to have it ready to go within a few days? I picture Jay walking into Mohan’s office like Ray Lewis waiting to tap that shelf. Hard to tell if Frank is a bigger fraud than this management team ATM.

User Image GermanBulle Posted - 6 days ago

$INO $MMAT $NBY $QQQ $SONN That’s what I try 2 tell in the morning 😉 others should Boom very soon 👀

User Image lamMBD Posted - 1 week ago

$SONN Looking good. Way undervalued Huge upside!!! Still under the radar. Love it! MBD

User Image GermanBulle Posted - 1 week ago

$SONN and $MMAT reversal IMO in progress Watch out! $INO has 2 break $ 12 - 12,5 … hidden pearl $NBY glimmer of hope 2day. But my status 4 that stock remains: trash! Change possible $QQQ new dangerous record in progress ??? As always. My opinion no advice !

User Image PennyGoddess Posted - 1 week ago

$SONN They tried shaking this back under $2 this week. We held strong. Lets see if we can break thru tomorrow to finish the high for the week!

User Image Tyjelly Posted - 1 week ago

$SONN

User Image lamMBD Posted - 1 week ago

$SONN Matter of time! Sooner than later. Let’s go SONN! MBD

User Image Gratz34 Posted - 1 week ago

$SONN Thank goodness we’re back to normal, entire portfolio green except sonn. just like its supposed to be lol

User Image Jackie_Treehorn Posted - 1 week ago

$SONN

User Image Jackie_Treehorn Posted - 1 week ago

$SONN

User Image PennyGoddess Posted - 1 week ago

$SONN Don't think we are gonna see that lol but the point is we have a valuable technology that big players can use. I think the $18-$41 price targets are realistic.

User Image PennyGoddess Posted - 1 week ago

$SONN AstraZeneca buys Fusion for $2 billion. They have a unique platform for targeting cancer cells. Sound familiar? Our targeting technology will enhance any existing cancer drug. Soon its' our turn.

User Image OutTheCloset Posted - 1 week ago

$SONN gonna be a microscope under his ass before this is done.

User Image Gratz34 Posted - 1 week ago

$SONN lol, king of the poster presentation

User Image PennyGoddess Posted - 1 week ago

$SONN And the good news continues....son-080 will be huge!

User Image RAPIDTRADX Posted - 1 week ago

$SONN 👀

User Image Stock_Titan Posted - 1 week ago

$SONN Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting https://www.stocktitan.net/news/SONN/sonnet-bio-therapeutics-to-present-preclinical-data-on-son-080-for-5n9szgd0hpoj.html

User Image TradingForGeorge Posted - 1 week ago

$SONN I see Markey is in the shadows liking posts again, and rather bizarrely unliking some after a while.

User Image saabgill Posted - 1 week ago

$SONN Good luck

Analyst Ratings
Chardan Capital Buy Feb 15, 24
Ladenburg Thalmann Buy Nov 27, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Dyrness Albert D. Director Director May 30 Buy 0.468 23,255 10,883 28,962 05/31/23
Bhatt Nailesh Director Director May 17 Buy 0.232 25,000 5,800 30,733 05/18/23
Mohan Pankaj Chairman, President.. Chairman, President and CEO May 15 Buy 0.223 371,600 82,867 553,331 05/15/23